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Abstract
The integration of in vitro cardiac tissue models, human induced pluripotent stem cells (hiPSCs) 
and genome-editing tools allows for the enhanced interrogation of physiological phenotypes and 
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the recapitulation of disease pathologies. Here, in a cardiac tissue model consisting of filamentous 
3D matrices populated with cardiomyocytes (CMs) derived from healthy wild-type hiPSCs (WT 
hiPSC-CMs) or from isogenic hiPSCs deficient in the sarcomere protein cardiac myosin binding 
protein C (MYBPC3−/− hiPSC-CMs), we show that the WT microtissues adapted to the 
mechanical environment with increased contraction force commensurate to matrix stiffness, 
whereas the MYBPC3−/− microtissues exhibited impaired force-development kinetics regardless 
of matrix stiffness and deficient contraction force only when grown on matrices with high fiber 
stiffness. Under mechanical overload, the MYBPC3−/− microtissues had a higher degree of 
calcium transient abnormalities, and exhibited an accelerated decay of calcium dynamics as well 
as calcium desensitization, which accelerated when contracting against stiffer fibers. Our findings 
suggest that MYBPC3 deficiency and the presence of environmental stresses synergistically lead 
to contractile deficits in the cardiac tissues.
Myosin binding protein-C cardiac isoform (MYBPC3) is a thick filament accessory protein 
of the striated muscle sarcomere A-band, and mutations in MYBPC3 are implicated in both 
Hypertrophic Cardiomyopathy (HCM) and Dilated Cardiomyopathy (DCM)1. The 
molecular mechanisms by which MYBPC3 mutations lead to the contractile deficits for 
DCM phenotypes remain elusive, while increasing reports from mouse models indicated that 
stress played a role in the initiation and progression of the physiopathology process 
associated with MYBPC3 mutations2. Currently, hiPSC technology has provided previously 
unanticipated possibilities to model human heart diseases in cell culture, but these models 
have tended to simplify the diseases as monogenic, hereditary forms of diseases, which 
neglects the diversity in disease phenotypes resulting from genetic-environmental 
interactions. Mechanical cues such as afterload, play a particularly important role in the 
normal function of the heart and the pathogenesis of diseases like cardiomyopathy. 
Incorporating environmental stresses such as mechanical cues into engineered hiPSC-based 
tissue models would provide the opportunity to model disease phenotypes with high 
precision.
3D engineered cardiac tissue models that mimic native tissue structures have been developed 
using a variety of methodologies and materials, which share a common process of hiPSC-
CMs encapsulation into external hydrogels3,4. To promote hiPSC-CMs alignment and 
formation of physiologically relevant tissue structures, the 3D cardiac tissues are anchored 
between two flexible cantilevers, which also served as a force sensor5–7. However, this 
measurement is compromised by the complex mechanical and biochemical contribution of 
extracellular matrix (ECM) hydrogels such as collagen, which alter tissue formation, 
mechanical properties8 and cellular contractile forces8. Therefore, self-assembled cardiac 
tissues relying on endogenous secretion of a cardiac specific extracellular matrices (cECM) 
are being explored for more consistent tissue self-assembly and remodeling9.
The biophysical microenvironment plays a critical role in cardiac pathophysiology. For 
example, the afterload against which the heart contracts directly relates to the mechanical 
stretch on CMs and plays an important role in the pathogenesis of DCM10. Contraction 
force, a key component of cardiac function, is continuously regulated by the surrounding 
environment11. The contraction force of hiPSC-CMs has been deemed as one of the essential 
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parameters for the evaluation of normal mature cardiac function, response to 
pharmacological interventions, and indication of disease phenotypes12–14. The force sensors 
used in the cardiac tissue models not only reported the contraction forces generated by 
hiPSC-CMs, but also naturally becomes the external mechanical load that regulates the 
cardiac tissue remodeling and function. In traction force microscopy, variation of substrate 
stiffness altered the myofibril organization of 2D micropatterned hiPSC-CMs, demonstrating 
substrata with optimal stiffness improved the contractile activity of hiPSC-CMs15. In 3D 
cardiac tissue models, flexible cantilevers used to anchor cardiac tissues also presented a 
rigid external structure to mimic in vitro cardiac tissue afterload16. Increase of the 
mechanical load to hiPSC-CMs from patient-specific and genome-engineered hiPSCs 
facilitated better modeling of DCM associated with TTN gene mutations17. In contrast, 
optimal mechanical load was critical for the 3D maintenance and maturation of hiPSC-CMs 
with highly organized sarcomeres, as well as increased adherens and gap junction 
formation18.
To address the hypothesis that tissue mechanical resistance to contraction can regulate CM 
sensitivity to the loss of MYBPC3, in the absence of complex interactions between cells and 
natural ECM derived gels, we created a cardiac tissue model that employed highly ordered 
3D fibers. The structure and mechanical properties of these fibers promoted cardiac tissue 
self-assembly and dynamic remodeling. Using two-photon polymerization (TPP), we created 
different filamentous matrices by fabricating precisely defined, ultra-high aspect ratio 
synthetic parallel fibers with different fiber diameters (i.e., 5 µm and 10 µm). Although these 
fibers have constant elastic modulus, the thicker fibers have a higher mechanical resistance 
to cellular contraction than thinner fibers. We populated WT hiPSC-CMs, or isogenic 
MYBPC3−/− hiPSC-CMs that completely lack expression of the sarcomere protein 
MYBPC3. WT cardiac microtissues adapted their contraction velocity and contraction force 
to the alternations of mechanical load. In contrast, MYBPC3−/− cardiac microtissues 
exhibited impaired force relaxation kinetics, but only exhibited defects in total systolic 
contractile force, compared to WT microtissues, when challenged with stiffer fibers. These 
results suggest that the cardiac tissue’s mechanical microenvironment facilitated the 
modeling of contractile deficits associated with the absence of MYBPC3 protein. 
Incorporation of appropriate mechanical resistance to cardiac contractility will likely be an 
important aspect of future efforts to model human heart disease in vitro.
RESULTS
Matrix fabrication and cardiac microtissue self-assembly and remodeling
Filamentous matrices were fabricated using TPP that produced scaffolds with highly defined 
micro and nano-scale features (Figure S1a, Movie S1)19–21. Based on previous studies, we 
concluded that the filamentous matrices, consisting of parallel fibers with 500 µm fiber 
length in Y-axis direction, 50 µm fiber spacing in X-axis direction, and 30 µm layer spacing 
in Z-axis, could robustly generate 3D condensed cardiac microtissues22 (Figure S1b). In this 
study, we fabricated multiple matrices within one pair of glass coverslips by separating 
cohorts of fiber matrices with 2 mm spacing in X-axis (Figure S1b). This design not only 
increased the throughput, but also made the fiber deflection easier to measure for contraction 
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force calculations. Scanning electron microscopy confirmed a matrix with parallel fibers, 
and the ability to control fiber diameter (e.g., 5 µm and 10 µm) (Figure S1c).
We seeded hiPSC-CMs onto filamentous matrices without any additional cell-encapsulating 
ECM gel. Generation of 3D cardiac microtissues required a relatively purified hiPSC-CM 
population and consistent cell handling procedures (Figure S2a). Purification 
procedures23,24 can routinely produce highly purified CM populations (cTnT+ cells > 95%). 
However, 3D engineered cardiac microtissues require a stromal cell or fibroblast population 
to enhance the mechanical integrity and connectivity of tissues9,25,26. Instead of six days of 
treatment with lactate purification media, we treated our cells for only four days, which 
resulted in a mixed hiPSC-CMs population (TNNT2+ cells ~ 80%, Figure S2b–c).
The hiPSC-CMs seeded on the filamentous matrices self-assembled into 3D cardiac 
microtissues (Z-axis thickness ~ 60 µm, Figure S3a,b) and maintained a stable beat rate after 
5-day of culturing. The cardiac microtissues continuously and progressively remodeled in 
response to the passive mechanical load of the fibers and active tissue contraction. The beat 
rate, contraction velocity, contraction force, and width of the individual cardiac microtissues 
were measured every 5 days to track the tissue remodeling associated with the change of 
functional readouts. Since the individual fibers were fixed onto the glass coverslips at both 
ends, the contracting cardiac microtissues were only able to deform the fibers in the X-
direction, but not in Y-direction (Movie S2). This mechanical constraint resulted in the 
anisotropic contraction with higher contraction along the X-axis compared to the Y-axis, as 
defined by contraction heatmaps (Figure 1a). We calculated the ratio of contraction velocity 
in the X and Y directions, and found a significant increase in the ratio from Day 5 to Day 20 
(Figure 1b). We also observed that the microtissues condensed in the direction of the Y-axis, 
but maintained the integrity along the X-axis, resulting in a significant decrease in the tissue 
cross-section areas (Z-Y direction) from Day 5 to Day 10 – 20 (Figure 1c). This data 
suggested that the change in tissue shape occurred simultaneously with the orientation of the 
contraction directions, thus anisotropic contraction and anisotropic tissue shape reinforced 
each other during the tissue remodeling process.
Mechanical load affected cardiac microtissue contractile functions
To test the hypothesis that mechanical overloading influences cardiac tissue functions, we 
created matrices with different fiber diameter. By changing fiber diameter, we could change 
the fiber bending stiffness to modulate the mechanical load to the cardiac microtissues 
assembled around the fibers. Based on atomic force microscopy (AFM) calibration of 
individual fibers, we calculated the elastic modulus of the material as 183.9 ± 11.7 MPa, 
which refers to the linear ratio of force load and deformation of the fiber. Although the 
elastic modulus is the same for both fibers, the fiber bending stiffness against which cells 
must contract is proportional to the square of fiber diameter, thus 5 µm fibers are much 
easier to be bend compared to 10 µm fibers. We did not observe a significant difference in 
the beat rate of the cardiac microtissues between 5 µm matrices and 10 µm matrices, but the 
beat rate slightly increased from Day 5 – 10 to Day 15 – 20 (Figure 1d). Likely because 5 
µm fibers are easier to be bend, we found higher maximal contraction velocity for cardiac 
microtissues assembled on the 5 µm matrices compared to 10 µm matrices (Figure 1e). This 
Ma et al. Page 4
Nat Biomed Eng. Author manuscript; available in PMC 2019 April 25.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
data suggested that modulating the mechanical load of tissue microenvironment via 
changing the fiber bending stiffness altered the contractile functions of cardiac microtissues.
We used the deflection of individual fibers to calculate the force of contraction. By assuming 
all the forces throughout the tissue cross-section were evenly distributed and parallel (Figure 
S4a), we calculated the point force exerted on individual fiber based on the fiber deflection 
and force position (where the maximal deflection locates) measured in a series of recorded 
images (Figure S4b). Using this point force, we could also calculate the total force generated 
by the cardiac microtissues. Through theoretical calculations, we found that the force 
measured by 10 µm fiber was approximately 10-fold higher than the force measured by 5 µm 
fiber with the same fiber deflection and force position (Figure S4d,e). Therefore, artificially 
applying the forces at the center region of the fiber with 1 µN to a 5 µm fiber and 10 µN to a 
10 µm fiber, we could determine the stress generated on the fibers through COMSOL 
numerical simulation. High stress occurred at the center region of the fiber, where the force 
was applied, and also occurred at two ends of the fiber, where the fiber was fixed at both 
sides of the glass coverslips (Figure S4c, Movie S3).
Cardiac preload is defined as end-diastolic myocardial wall tension. In this study, we refer to 
preload as the passive tension exerted by the fibers at two edges of the matrix to the diastolic 
cardiac microtissue at the resting state. The load opposing shortening of the ventricular 
muscles is termed cardiac afterload. Here, the cardiac tissue afterload is defined as the fiber 
tension against the systolic cardiac microtissue at the maximal contraction (Figure 2a). The 
afterload considerably increases when the cardiac microtissues contract against the stiffer 
fibers. Based on the fiber deflections – force relationship discussed above, we calculated the 
static forces (diastole) and contraction forces (systole) for the cardiac microtissues 
assembled on both 5 µm and 10 µm matrices, and found that cardiac microtissues produced 
higher forces when grown on the matrices with stiffer. We found that the static forces 
increased significantly from Day 5 to Day 20 for the cardiac microtissues assembled on both 
5 µm and 10 µm matrices (Figure 2b,c), whereas the contraction forces increased 
significantly only when the microtissues grew on the 10 µm matrices, not on the 5 µm 
matrices (Figure 2d,e). Self-assembled WT hiPSC-CMs on the 10 µm filamentous matrices 
adapted to the high stiffness and increased the contraction force through mechanical 
overloading.
Isogenic MYBPC3−/− cardiac microtissues exhibit force deficits without structural disarray
To test the hypothesis that mechanical resistance synergizes with genetics to cause 
contraction deficits, we harnessed TALEN-assisted gene-editing to create an isogenic human 
homozygous MYBPC3 null cardiac microtissue model. MYBPC3 is a thick filament 
associated protein, which is thought to play a principally structural role for stabilization of 
the sarcomere sliding during contraction27,28 (Figure S5a). Fluorescent images of WT 
hiPSC-CMs showed the MYBPC3 protein aligned with ATCN2 protein, indicating the 
structural relationship of A bands and Z discs (Figure S5b). Furthermore, this protein binds 
to thin and thick filaments, thereby regulating the probability of cross-bridge interactions, 
which in turn controls the rate of force development and relaxation in cardiac muscles29.
Ma et al. Page 5
Nat Biomed Eng. Author manuscript; available in PMC 2019 April 25.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
To test the hypothesis that environmental conditions could modulate the contraction deficits 
caused by loss-of-function mutations, we focused this initial study on a severe loss-of-
function caused by complete, homozygous knockout of MYBPC3. The isogenic 
homozygous MYBPC3−/− hiPSC cell line was developed using TALEN-based genome 
editing (Figure S5c). hiPSC-CMs derived from MYBPC3−/− hiPSC parent cells showed a 
complete loss of MYBPC3 mRNA and protein (Figure S5e,f). MYBPC3−/− hiPSC-CMs 
formed the 3D anisotropic cardiac microtissues on both 5µm and 10µm filamentous matrices 
(Movie S4), so we could determine how mechanical overload affected the contractile 
behaviors in MYBPC3−/− cardiac microtissues. There was no significant difference in the 
static forces between WT and MYBPC3−/− cardiac microtissues on both 5 µm and 10 µm 
matrices (Figure 3a,b), which suggested the absence of MYBPC3 had no effect on cardiac 
preload. Furthermore, we did not observe a difference in the contraction forces between 
MYBPC3−/− and WT cardiac microtissues on 5µm fibers. However, we observed a marked 
inhibition in contractile force development in MYBPC3−/− cardiac microtissues, compared 
to WT, on 10µm fiber matrices (Figure 3c,d). We also found that the MYBPC3−/− cardiac 
microtissues showed higher contraction velocity compared to WT, and this velocity 
difference between WT and MYBPC3−/− cardiac microtissues was exaggerated on 10 µm 
matrices (Figure 3e,f). Independent of either tissue type, the magnitude of force was greater 
on 10 µm matrices and the contraction velocities were significantly higher on 5 µm matrices. 
These results suggested that modulating the mechanical load against which engineered 
cardiac tissue contracted facilitated the manifestations of contractile deficits due to absence 
of MYBPC3 protein. To rule out any effects of contraction abnormalities on these results, 
we only assessed the force of systolic contraction in microtissues that had regular beating 
behaviors, defined SD/mean of beating relaxation decay time less than 0.1.
Since we found substantial reduction of contraction forces from MYBPC3−/− cardiac 
microtissues on 10 µm matrices, we subsequently evaluated the structural characteristics 
between WT and MYBPC3−/− cardiac microtissues on 5 µm and 10 µm matrices at Day 20 
(Figure 4a,c). Surprisingly, we found no significant differences on tissue cross-section areas 
(Figure 4b), sarcomere organization (Figure 4d,e) and connexin 43 (Cx43) expression 
(Figure S6) from either of the two genotypes or fiber matrix types. These results suggested 
that absence of MYBPC3 protein did not induce gross tissue shape remodeling or sarcomere 
disarray at the in vitro tissue level within 20-day culture, but did play an important role in 
force development responding to the external mechanical overload.
Isogenic MYBPC3−/− cardiac microtissues exhibit abnormalities in force and calcium 
dynamics
As structural deficiencies were not sufficient to explain the marked force deficits in 
MYBPC3−/− cardiac microtissues on stiff fiber matrices, next investigated contractile force 
kinetics. Since MYBPC3 protein is thought to regulate the force development during cardiac 
contraction30, we plotted the force kinetics curves for WT and MYBPC3−/− cardiac 
microtissues on 5 µm and 10 µm matrices at Day 20. By multiplying the force and velocity, 
we also plotted the power kinetics curves, and measured the area under the curve as the total 
energy consumed by the cardiac microtissues to complete one contraction. On both 5 µm 
and 10 µm matrices, MYBPC3−/− cardiac microtissues developed the maximal contraction 
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forces faster than WT microtissues (Figure 5a,c). Since the force magnitude was similar 
between WT and MYBPC3−/− cardiac microtissues on the 5 µm matrices, higher contraction 
velocity led to higher power output and more energy consumption (the area of power 
kinetics curve) of the MYBPC3−/− cardiac microtissues (Figure 5b). On the other hand, 
MYPBC3−/− cardiac microtissues on the 10 µm matrices developed significantly lower 
contraction forces, less power output, but similar energy consumption compared to the WT 
microtissues (Figure 5c,d). The same energy consumption, but low force production from 
MYBPC3−/− cardiac microtissues indicated that absence of MYBPC3 protein impaired the 
cardiac microtissues to contract in an energy-efficient manner. To further analyze the force 
kinetics, we measured the upstroke time to peak force (τmax), early decay time of 50% peak 
force (τ50) and late decay time of 75% peak force (τ75). We found no significant difference 
of the cardiac microtissues between 5 µm and 10 µm fiber matrices, but MYBPC3−/− cardiac 
microtissues were statistically faster to reach to the peak force (τmax, Figure 5e). Compared 
to the WT microtissues, MYBPC3−/− microtissues exhibited no significant difference on 
early decay time (τ50, Figure 5f), but a slower late decay time (τ75, Figure 5g). This delayed 
force relaxation is consistent with an HCM-like phenotype1.
Previous studies have noted that hiPSC-CMs derived from patients with familial 
cardiomyopathy are more prone to electrophysiological abnormalities such as Early After 
Depolarizations (EADs)31. To determine how the abnormalities on the calcium handling 
occurred on MYBPC3−/− cardiac microtissues under mechanical overload, we generated 
hiPSC harboring the genetically-encoded Ca2+ reporter, GCaMP6f, which was inserted into 
the AAVS1 locus on both WT and MYBPC3−/− hiPSC lines (Figure S5d), allowing direct 
measurements of calcium dynamics. The fluorescent fluctuation of GCaMP6f signal from 
the GCaMP6f cardiac microtissue assembled on the filamentous matrices indicated the Ca2+ 
dynamics of the cell, (Figure 6a and Movie S5), caused by the combination of L- type 
calcium channels and calcium-induced calcium release from the sarcoplasmic reticulum, 
downstream of the action potential32.
We generated GCaMP6f-WT and GCaMP6f-MYBPC3−/− cardiac microtissues on both 5 µm 
and 10 µm matrices, and recorded the calcium transient via the GCaMP6f reporter (Figure 
6b). We first analyzed calcium dynamics in the microtissues that did not exhibit gross 
calcium transient abnormalities (this was defined by measuring the decay time, τ75, of the 
calcium transient, and selecting tissues with SD/mean τ75 < 0.1). Within this set of tissues, 
we found that there was no effect of MYBPC3 deficiency on the overall intensity of GCaMP, 
suggesting that the overall amount of Ca2+ entering cells remained the same. However, we 
did observe increased GCaMP maximum, corresponding to greater calcium intake, when 
both WT and MYBPC3 deficient tissues were challenged to contract against stiffer fibers 
(Figure 6c). By analyzing calcium transient decay dynamics, we observed no significant 
difference on early decay time (τ50, Figure 6d), but did find that MYBPC3−/− cardiac 
microtissues on both 5µm and 10µm fiber matrices exhibited faster late decay times (τ75) of 
calcium transient compared to WT microtissues (Figure 6e).
Although EADs were rare events in all microtissues (Figure 6f), we did observe a 
significantly increased probability of EAD events in MYBPC3−/− microtissues contracting 
against stiff fibers (Figure 6g,h). We also analyzed the calcium sensitivity of GCaMP6f-WT 
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and GCaMP6f-MYBPC3−/− cardiac microtissues on both 5 µm and 10 µm matrices, and 
found the trend of calcium desensitization of MYBPC3−/− microtissues comparing to WT 
microtissues (Figure 6i). More importantly, the cardiac microtissues appeared to become 
further desensitized to extracellular calcium when contracting against the stiffer matrices. 
The mismatch between faster decay of calcium transient and slower decay of contraction 
force indicated the importance of MYBPC3 protein for regulating the cardiac contractility 
through excitation-contraction coupling. This is consistent with data obtained in cell-free, 
reconstituted protein assays that implicate MYBPC3 protein as a potential “molecular 
brake” controlling the rate of force development and relaxation in heart muscle30.
To begin to understand the mechanisms through which stiffer matrices affected pathology of 
MYBPC3−/− hiPSC-CMs, we profiled gene expression (102 genes) for the WT and 
MYBPC3−/− cardiac microtissues on 10 µm matrices (Figure 7a). Although we found no 
significant difference in either sarcomere structural deficit (MYH6, MYH7) or calcium 
handling malfunction (CALM1, CALM3), which have been typically related to HCM, we 
identified four genes (EP300, CREBBP, HDAC1 and GATA4) that were significantly up-
regulated in the MYBPC3−/− microtissues (Figure 7b). We also found the expression of 
human brain natriuretic peptide (hBNP) between WT and MYBPC3−/− cardiac microtissues 
only became significantly different when the cardiac microtissues grew on 10 µm matrices, 
suggesting that the observed loss of contraction force is concurrent with molecular 
indicators of disease progression in the MYBPC3−/− microtissues (Figure 7c). Via confocal 
microscopy and quantitative fluorescent measurement, we determined the EP300 expression 
significantly increased on the cardiac microtissues grown on the 10 µm matrices compared 
to the ones on 5 µm matrices (Figure 7d). Furthermore, we found that EP300 expression on 
MYBPC3−/− cardiac microtissues was significant higher than WT microtissues on both 5 µm 
matrices and 10 µm matrices, suggesting that EP300 plays a key role in the synergy between 
genetic deficiency and mechanical overload in inducing contractile deficits (Figure 7e).
DISCUSSION
In this work, we combined hiPSC technology, genome editing tools, and advanced material 
processing to create a next-generation hiPSC-based cardiac tissue model, which 
recapitulated the synergism of genetic deficiencies and environmental stresses required to 
induce the life-threatening cardiomyopathies. We innovated the conventional TPP technique 
to enable fabrication of high aspect ratio (100:1) fibers with reasonable throughput, which 
ensured the structural support and force sensing function used in our cardiac tissue model33. 
Such aspect ratios are impossible to achieve with standard microfabrication technology. 
Furthermore, unlike other methods to create filamentous matrices like electrospinning, self-
assembly, 3D micropatterning of hydrogels, our TPP technique have unprecedented control 
over a wide range of matrix features deemed important in allowing immediate cell 
infiltration for 3D tissue formation and regulating tissue mechanical functions22. Not only 
harnessing the mechanical load of the fiber matrix as the environmental stress to the hiPSC-
CMs, we also used the genome-editing to engineer isogenic diseased hiPSC lines to 
precisely control the genetic background34,35, in order to understand the pathogenesis from a 
specific gene mutation and its interaction with environmental stress.
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Previous studies from MYBPC3 knockout mice exhibited impaired contractile properties 
with overall reduction in diastolic and systolic functions observed at the whole heart 
level36,37. Consistent with our hiPSC model, myofilament Ca2+ sensitivity of tension was 
also reduced in MYBPC3−/− mice with a right-shifted normalized Ca2+ tension curve 
relative to the WT mice. Our findings that MYBPC3−/− cardiac microtissues were viable and 
display well-developed sarcomeres, conflicting with previous hypothesis that MYBPC3 
protein plays essential structural roles for sarcomere assembly and stability. However, our 
study was consistent with the MYBPC3−/− mouse model, in which the well-organized 
sarcomere striation patterns were observed in nearly all sections of heart tissues36. Our 
results, together with mouse models, indicated that MYBPC3 protein is not an absolute 
requirement for the assembly and maintenance of organized sarcomeres and myofibrils, but 
serves a complimentary role in modulating cardiac contractile functions.
To examine the regulatory effects of MYBPC3 protein on cardiac contractile function, 
multiple heterozygous and homozygous mouse models have been established with 
confounding results. One in vitro homozygous MYBPC3−/− mouse tissue model 
demonstrated characteristic acceleration of contraction kinetics, a hyper-contractile HCM-
like disease phenotype38, while another homozygous tissue model demonstrated DCM-like 
reduced contractions39, indicating the complexity of genotype-phenotype correlation 
provoked by the MYBPC3 mutations. Recently, a tamoxifen-inducible MYBPC3−/− mouse 
model only demonstrated impaired diastolic function, but very mild systolic dysfunction 
under normal conditions40. However, if pressure overload was induced by transverse aortic 
constriction (TAC), these mice developed left ventricular dilation and reduced contractile 
functions. These results suggest that mechanical stress in the form of increased afterload 
may be required to observe phenotypes associated with MYBPC3 loss-of-function 
mutations. This is consistent with the observation that systemic resistance is a major risk 
factor for heart failure in the setting of cardiomyopathy10. These indications also lean 
towards the clinical findings that a subset of patients with HCM associated with 
heterozygous MYBPC3 truncated mutations could later develop left ventricular dilation and 
systolic dysfunction similar to DCM, otherwise known as “burnt out” phase HCM or end-
stage HCM. However, these murine-based in vivo models make it very difficult to 
specifically isolate the biomechanical etiology underlying the disease onset and process, as 
TAC or other maneuvers that increase cardiac afterload also affect global signaling through 
inflammation and other processes41. In contrast, our hiPSC-based in vitro model eliminates 
the complex changes in soluble milieu related to the maneuvers used in animal models for 
cardiac overload, and also allows the disease process to be modeled in genetically defined 
human cells.
Currently, hiPSC-based MYBPC3-related disease models have only been established at 
single cell or 2D monolayer levels. A previous report on patient-derived hiPSC-CMs 
carrying a heterozygous MYBPC3 mutation (c.2373dupG) micropatterned at single-cell 
level showed systolic dysfunction with lower contractile force generation compared to the 
healthy controls42. Consistent with the hypothesis that MYBPC3−/− genotypes reduce 
contractile force, a recent study using an allelic series of isogenic MYBPC3−/− hiPSC-CMs 
indicated a decrease in contractile force of single hiPSC-CMs as MYBPC3 dose was 
reduced43. In light of these studies, we decided to solely focus on the MYBPC3−/− hiPSC-
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CMs to develop an in vitro disease model, so that we could study how such contractile 
deficits due to absence of MYBPC3 protein would be altered by external mechanical 
overload and associated gene expression. Importantly, despite the extreme severity of 
homozygous loss-of-function of MYBPC3, we only observed pathological phenotypes when 
hiPSC-CMs were challenged to contract against overload. This suggests physical properties 
of the tissue microenvironment could be used as environmental stress to induce and 
deteriorate the contractile deficits resulted from the genetic deficiency.
In vitro modeling external mechanical load to cardiac tissues has been developed either by 
passive stretch of cardiac tissues mimicking the increase of preload44,45, or stiffening the 
flexible cantilevers to cardiac tissues mimicking the increase of afterload16,17,46. It has been 
suggested that in vitro systems of engineered cardiac tissues could unmask subtle 
abnormalities due to genetic deficiencies that were concealed by the compensatory 
mechanisms in intact animals47. Our model facilitated 3D tissue-like arrangement of hiPSC-
CMs, mimicked the increase of afterload, and assessed the effects of mechanical overload on 
cardiac functions. WT cardiac microtissues exhibited enhanced contractile functions in 
response to the increase of afterload. Furthermore, we assessed the contractile deficits of 
human MYBPC3−/− cardiac microtissues under low and high mechanical load, and found 
MYBPC3−/− microtissues only exhibited reduced systolic contraction force on the matrices 
with stiffer fibers. This data demonstrated that absence of MYBPC3 protein impaired 
physiological adaptation to the mechanical overload, induced contractile deficits, and 
activated pathological signaling.
Previous study on patient-derived hiPSC line harboring MYBPC3 mutation indicated 
myofibril disarray at single-cell level48. Although we observed clear functional deficits in 
the contractile behaviors of MYBPC3−/− cardiac microtissues, these did not directly 
correlate to marked changes in sarcomere structure, indicating that sarcomere disarray may 
be a consequence, rather than a cause of contractile dysfunction during the development of 
MYBPC mutation-related cardiomyopathies. This highlights the need for technologies, such 
as genetically-encoded sarcomere reporters25, which allow researchers to in vitro observe 
the timing of consecutive sequence for different hallmarks of cardiomyopathy from 
contractile deficits to structural disarray, or vice versa. Potentially, the combination of 
biomechanical cues with chemical-induced stress or prolonged culture would lead to 
structural deficiencies.
To begin understanding molecular mechanisms underlying how environment alters 
genotype-phenotype relationships, we performed proof-of-concept gene array studies and 
identified EP300-CBP-GATA4 as a cascade involved in overload-induced contractile deficits 
on MYBPC3−/− cardiac microtissues. It has been previously reported that downregulation of 
C/EBPβ in the heart was associated with overload-induced physiological hypertrophy49. The 
deactivation of C/EBPβ pathway was associated with up-regulation of CITED4, the EP300-
CBP interacting transactivator, which promoted the proliferation of CMs. In our study, we 
suggested that up-regulation of EP300-CBP was also associated with overload-induced 
contractile deficits, which was consistent with a previous study in which EP300 
overexpression led to hypertrophy of cardiomyocytes and the heart in vivo50. Pathological 
stress, such as pressure overload, alters cardiac gene expression and promotes the activation 
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of gene predominantly expressed in the fetal heart. From the MYBPC3−/− cardiac 
microtissues on 10 µm matrices, we only found significant increase of GATA4 expression, 
although expression of MEF2C and TBX5 also showed an increasing trend, though not 
statistically significant (p < 0.2). In previous studies, heart EP300 ChIP-sequencing reads 
were strongly enriched on GATA4 peaks51,52, suggesting that GATA4 directly interacted 
with EP300-CBP for synergistic gene activation of ANP, BNP and MYH7 promoters during 
myocardial hypertrophy53,54. In contrast to indirect means of inducing mechanical stress, 
such as chronic catecholamine exposure, direct manipulation of the biophysical properties of 
the in vitro cardiac microenvironment does not introduce additional signaling pathways (e.g. 
GPCR signaling) that complicate mechanistic studies.
MYBPC3 accounts for a significant proportion of familial cardiomyopathies, and is 
associated with both HCM and DCM. However, the molecular mechanisms linking 
MYBPC3 mutations to the pathogenesis of cardiomyopathy remain elusive. Our study 
emphasized the role of MYBPC3 protein in regulating cardiac contractile functions by using 
a homozygous MYBPC3 knockout isogenic hiPSC line, and demonstrated pronounced 
DCM-like contractile phenotypes (impaired systolic contraction force, faster decay of 
calcium dynamics, and calcium desensitization) on the MYBPC3−/− cardiac microtissues 
contracting against stiffer fibers. In future studies, our findings relating the importance of 
overload in modeling cardiomyopathy phenotypes could be leveraged to study the effects of 
more subtlety, heterozygous missense or truncated mutations typically found in patients. 
Importantly, the results obtained from this study with isogenic lines can be used as “training 
sets” to calibrate our system and provide “standards” for the subsequent studies on more 
diverse genetic backgrounds and greater variety of phenotypes.
METHODS
An expanded Methods section is included in the Supplementary Information, with more 
details on cell handling, motion tracking analysis, finite element modeling, immunostaining 
and microscopy, RT-qPCR. hBNP ELISA, flow cytometry, quantitative sarcomere analysis 
and statistical methods.
Fabrication of filamentous matrices
The filamentous matrices were fabricated by TPP using the photo-curable organic-inorganic 
hybrid polymer OrmoClear® (Micro resist technology). Briefly, OrmoClear® resin was first 
spin-coated, pre-baked and UV cured on the glass coverslips. Two glass coverslips with 
cured OrmoClear® thin layers were assembled as one set with 500 µm-thick spacers and 
filled with uncured OrmoClear®. Individual fibers were fabricated by single laser beam 
radiation of the uncured OrmoClear® through a high repetition rate femtosecond laser (pulse 
duration: ~ 400 femtosecond, repetition frequency: 1 MHz, wavelength: 1045 nm, FCPA 
µJewel D-400, IMRA America Inc.). The laser beam was frequency-doubled (wavelength: 
522 nm) by Lithium triborate (LBO) second harmonic nonlinear crystal (Newlight 
photonics) and focused at the interface between glass coverslip and OrmoClear® with 5× 
objective (N.A. = 0.14) (M Plan Apo, Mitutoyo). Fiber diameter was determined by the laser 
power and exposure duration, which was controlled through a mechanical shutter (Thorlabs). 
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5 µm fibers were fabricated by 3.7 mW power laser radiation for 0.9 seconds, whereas 10 
µm fibers were fabricated by 5.2 mW for 2 seconds. Fiber spacing was controllable by a 3D 
axis motorized stage with high precision of positioning (Aerotech, ANT95-XY-MP for X–Y 
axis and ANT95-50-L-Z-RH for Z axis). To fabricate several matrices within one set, we 
blocked the laser radiation during the movement from the end point of the previous matrix to 
the starting position of next matrix. After fiber fabrication, samples were hard-baked for 10 
minutes, developed for 30 minutes with a mixture of 2-Isopropyl alcohol and 4-Methyl-2-
pentanone (1:1, Sigma Aldrich), rinsed with 2-Isopropyl alcohol and DI water 3 times, and 
dipped in 70% ethanol for sterilization.
Generation of 3D cardiac microtissues
Three sets of glass devices were placed into one well of a 6-well plate, rinsed with 
Dulbecco’s phosphate buffered saline (DPBS, Gibco) three times, and diluted Matrigel was 
adsorbed for at least 1 hour. Diluted Matrigel was rinsed off before cell seeding, leaving a 
thin coating on the individual fibers, instead of Matrigel gel. Cryopreserved hiPSC-CMs 
were thawed into EB20 media and plated onto Matrigel-coated 6-well plate with RPMI/
B27+C media supplemented with 10 µM Y-27632. After 4 days recovery in RPMI/B27+C 
media, the cells were singularized by 0.25% trypsin, quenched with EB20 media, and seeded 
into filamentous matrices without ECM proteins or additional Matrigel at a density of 3 
million/mL RPMI/B27+C media supplemented with 10 µM Y-27632. After four hours, 
another 4 mL RPMI/B27+C media supplemented with 10 µM Y-27632 was added into each 
well to cover the whole set of filamentous matrices. The media was switched to RPMI/
B27+C media the next day and changed every 2 days. Videos of cardiac microtissue beating 
were recorded every 5 days for motion tracking analysis and force measurement.
Fiber characterization
The elastic modulus of the fiber (Ef) was measured by atomic force microscopy (AFM, 
XE-100, Park Systems) with tip-less AFM cantilevers (TL-CONT-SPL and TL-FM-SPL, 
Nanosensors). Fiber shape was assumed to be a cylinder with a circular cross-section. 
Hence, the Young’s modulus of the fiber was calculated via equation (1).
E f =
64KdcL
3
3πD4(d f − dc)
(1)
with length (L) and diameter (D) of the fiber, deflection of the AFM cantilever (dc) and 
relative deflection of the fiber (df). The spring constants (K) of tip-less AFM cantilevers 
were measured using the thermal tuning method55 and calculated to be 0.0636 N/m using 
AFM software (XEI, Park system). Finally, Young’s modulus of the fibers with both 5 µm 
and 10 µm diameters was calculated to be 183.9 ± 11.7 MPa.
Force measurement
To calculate the contraction forces of the whole cardiac microtissue, we made three 
assumptions: (1) the forces were evenly distributed across the tissue cross-section (tissue 
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width multiplying tissue thickness W (y-axis)·H (z-axis)); (2) all the force vectors were 
parallel each other and perpendicular to the fiber axis; and, (3) the fiber had a circular cross-
section. Based on those assumptions, we calculated the total force (F) generated by the 
cardiac microtissue by integrating the distributed force (f) across entire tissue cross-section. 
To calculate the generated force of whole cardiac tissue, the individual fiber point force (F’) 
was calculate based on the beam deflection theory at the position with maximal fiber 
deflection. Using the series of single-frame image recorded for cardiac tissue beating, we 
measured the fiber deflection (δ) at specific positions (a) between two consecutive images, 
so that we could calculate the point force (F’) applied to the fibers based on equation (2) 
with Young’s modulus (Ef), length (L) and diameter (D) of the fiber.
F′ =
3πE fD
4(2a + L)2
128a3(L − a)2
(2)
The distributed force (f) was calculated by dividing the individual fiber point force (F’) by 
the half-cylinder surface area of the applied force to the fiber. Finally, integrating the 
distributed force across entire tissue cross-section, we calculated the total force (F) 
generated by the cardiac microtissues. The static force was calculated based on the preload 
fiber defection that was measured with the cardiac microtissue in the resting diastolic state, 
whereas the contraction force was calculated based on the afterload fiber defection that was 
measured with cardiac microtissue at maximal contraction, systolic state. All the contractile 
function analysis was performed only on the microtissues with regular contraction kinetics 
(normalized errors in τ75 less than 0.1).
Calcium transient dynamics analysis
For calcium imaging, GCaMP6f hiPSC-CMs were differentiated, purified, cryopreserved, 
seeded, and formed the microtissues on the filamentous matrices for continuous calcium 
imaging at Day 20. The calcium flux images were recorded at 30 frames per second for 10 
seconds using a Nikon Eclipse TS100F microscope with temperature-controlled stage and 
Hamamatsu ORCA-Flash4.0 V2 digital CMOS camera. The amplitude and kinetics of the 
calcium signals were analyzed using custom Matlab code based on work by Laughner and 
colleagues56. When reporting calcium amplitude and dynamics, we first assessed the 
regularity of the τ75 of decay, defined as the standard deviation divided by the mean (SD/
mean) of the τ75. Only microtissues with SD/mean of τ75 < 0.1 were selected for further 
analysis.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Cardiac microtissues remodeling on filamentous matrices
(a) WT Cardiac microtissues on a 5 µm fiber matrix remodeled their shape from Day 5 to 
Day 20. Contraction heatmaps showed anisotropic contraction with higher contraction in the 
X-direction compared to the Y-direction. The motion close to the glass substrates in the 
heatmaps of mean Y velocity was only resulted from fiber movement during tissue 
contractions, since no tissue grown at these locations. Scale bar, 100 µm. The progressive 
tissue remodeling manifested as (b) an increase of the ratio of mean contraction between X-
axis and Y-axis directions (ANOVA Bonferroni’s multiple comparison test, p = 0.0086 for 5 
µm matrices and p = 0.0004 for 10 µm matrices), and (c) a decrease of the tissue cross-
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section (Z-Y direction) by comparing Day 5 to Day 10–20 (ANOVA Bonferroni’s multiple 
comparison test, p = 0.0001 for 5 µm matrices and p = 0.0135 for 10 µm matrices). (d) The 
beat rate of cardiac microtissues slightly increased comparing Day 5–10 and Day 15–20 
(two-tailed student t-test, p = 0.005 for 5 µm matrices and p = 0.004 for 10 µm matrices). By 
investigating the effect of tissue mechanical environment on cardiac contractility, we found 
(d) no significant difference on beat rate, but (e) much higher maximal contraction velocity 
for the cardiac microtissues assembled on 5 µm matrices than the ones on 10 µm matrices 
(two-tailed student t-test, p = 0.0035 for Day 5, p = 0.0052 for Day 10, p = 0.000131 for 
Day 15, and p = 0.0000415 for Day 20). Data (n = 6): box plot with minimum, maximum, 
median, 25% and 75%.
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Figure 2. Force measurement based on fiber deflection
(a) The static force and contraction force were calculated based on preload deflection at 
diastolic status and afterload deflection at systolic status. Scale bar, 100 µm. The static 
forces increased during 20-days culturing for WT cardiac microtissues assembled on both 
(b) 5 µm and (c) 10 µm matrices (ANOVA Bonferroni’s multiple comparison test, p = 
0.0499 for 5 µm matrices and p = 0.0387 for 10 µm matrices). (d) The contraction forces 
showed no significant increase for WT cardiac microtissues on 5 µm matrices, (e) whereas 
the increase became significant for the microtissues on 10 µm matrices (ANOVA 
Bonferroni’s multiple comparison test, p = 0.0147 for 10 µm matrices). At each time point, 
the magnitudes of the static and contraction forces were significantly higher for WT cardiac 
microtissues grown on 10 µm matrices than the ones grown on 5 µm matrices. Data (n = 6): 
box plot with minimum, maximum, median, 25% and 75%.
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Figure 3. Contractile deficits of MYBPC3−/− cardiac microtissues
Comparing WT to MYBPC3−/− cardiac microtissues showed no significant difference on 
static forces for the microtissues on both (a) 5 µm and (b) 10 µm matrices, and (c) no 
difference on contraction forces for the microtissues on 5 µm matrices, (d) but lower 
contraction forces at Day 15 & 20 for the MYBPC3−/− microtissues only on 10 µm matrices 
(two-tailed student t-test, p = 0.0016 for Day 15, p = 0.0081 for Day 20). MYBPC3−/− 
cardiac microtissues showed higher maximal contraction velocity for the cardiac 
microtissues assembled on both (e) 5 µm (two-tailed student t-test, p = 0.0366 for Day 20) 
and (f) 10 µm matrices (two-tailed student t-test, p = 0.0388 for Day 15, p = 0.0475 for Day 
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20) compared to WT cardiac microtissues. At each time point, the magnitudes of the static 
and contraction forces were significantly higher for WT and MYBPC3−/− cardiac 
microtissues grown on 10 µm matrices, and contraction velocities were significantly higher 
for the microtissues grown on 5 µm matrices. Data (n = 6): box plot with minimum, 
maximum, median, 25% and 75%.
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Figure 4. No structural disarray on MYBPC3−/− cardiac microtissues
(a) Bright-field microscopy showed (b) no significant difference on tissue cross-section 
between WT and MYBPC3−/− cardiac microtissues assembled on 5 µm and 10 µm matrices 
at Day 20. Scale bar, 100 µm. (c) Confocal microscopy showed (d) no significant difference 
on sarcomere alignment index between WT and MYBPC3−/− microtissues assembled on 5 
µm and 10 µm matrices at Day 20. Scale bar, 50 µm. Confocal images of (e) sarcomere 
organization of WT and MYBPC3−/− cardiac microtissues growing on 5 µm and 10 µm fiber 
matrices. Scale bar, 20 µm. Data b&d (n = 12): mean with all data points. Image e&f: 
representative confocal images of 12 samples.
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Figure 5. Mechanical load altered contractile force dynamics
(a) The force development of MYBPC3−/− cardiac microtissues on 5 µm matrices was faster 
than WT tissues, but no difference in the magnitude. (b) MYBPC3−/− cardiac microtissues 
on 5 µm matrices showed higher power output and energy consumption compared to WT 
microtissues. (c) MYBPC3−/− cardiac microtissues on 10 µm matrices showed (c) impaired 
force generation and (d) lower power output compared to WT microtissues. (e) MYBPC3−/− 
cardiac microtissues had faster contraction reaching to the peak force (τmax) compare to the 
WT microtissues (two-tailed student t-test, p = 0.000633 for 5 µm matrices, p = 0.000104 for 
10 µm matrices). (f) Although no significant difference on early decay time of 50% peak 
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force (τ50), (g) MYBPC3−/− cardiac microtissues had a longer late decay time of 75% peak 
force (τ75) (two-tailed student t-test, p = 0.00315 for 5 µm matrices, p = 0.0194 for 10 µm 
matrices). Data a–d (n = 8): all data with curve fitting. Data e–g (n = 8): box plot with 
minimum, maximum, median, 25% and 75%.
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Figure 6. Calcium transient abnormalities on MYBPC3−/− cardiac microtissues
(a) The calcium fluctuation of a GCaMP6f-WT cardiac microtissue growing on a 10 µm 
fiber matrix. (b) We were able to quantify the calcium dynamics based on the GCaMP 
fluorescent intensity recorded from GCaMP6f cardiac microtissues. (c) Cardiac microtissues 
growing on 10 µm matrices had higher peak intensity comparing to the ones on 5 µm 
matrices (two-tailed student t-test, p = 0.0288 for WT, p = 0.00152 for MYBPC3−/−). (d) 
Although there was no significant difference on early decay time (τ50), (e) GCaMP6f-
MYBPC3−/− cardiac microtissues had a shortened late decay time (τ75) on both 5 µm and 10 
µm fiber matrices (two-tailed student t-test, p = 0.00104 for 5 µm matrices, p = 0.000162 for 
10 µm matrices). (f) Representative traces for regular calcium dynamics and EAD-like 
calcium dynamics measured from GCaMP6f-MYBPC3−/− cardiac microtissues. The 
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GCaMP6f-MYBPC3−/− cardiac microtissues showed significant (g) higher variations on 
normalized error in τ75 (two-tailed student t-test, p = 0.0253 for 10 µm matrices) and (h) 
higher possibility of EAD behaviors when growing on 10 µm matrices (two-tailed student t-
test, p = 0.0178 for 10 µm matrices). (i) Calcium desensitization was found on MYBPC3−/− 
cardiac microtissues comparing to WT microtissues, and microtissues contracting against 
stiffer fibers. Data c–h (n = 10): box plot with minimum, maximum, median, 25% and 75%. 
Data i (n = 6): mean ± SD.
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Figure 7. EP300-GATA4 directed contractile deficits due to mechanical stress
(a) At Day 20, 102 genes were profiled for WT and MYBPC3−/− cardiac microtissues 
growing on 10 µm matrices. (b) Gene expression of EP300 (p = 0.0798), CREBBP (p = 
0.022), HDAC1 (p = 0.0331) and GATA4 (p = 0.034) on MYBPC3−/− cardiac microtissues 
significantly increased compared to WT cardiac microtissues grown on 10 µm filamentous 
matrices (two-tailed student t-test). (c) At Day 20, human BNP expression on MYBPC3−/− 
cardiac microtissues was found to be significantly higher than WT cardiac microtissues only 
grown on 10 µm matrices (two-tailed student t-test, p = 0.0478 for matrices comparison, p = 
0.0015 for WT/ MYBPC3−/− comparison on 10 µm matrices). (d) Confocal images of p300 
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fluorescent staining on both WT and MYBPC3−/− cardiac microtissues on 5 µm and 10 µm 
filamentous matrices. (e) Quantitative fluorescent analysis on p300 expression showed the 
cardiac microtissues on 10 µm matrices had higher p300 expression than the ones on 5 µm 
matrices, and MYBPC3−/− cardiac microtissues had higher p300 expression than WT 
microtissues (two-tailed student t-test, p = 0.0269 for matrices comparison, p = 0.00504 for 
WT/ MYBPC3−/− comparison on 5 µm matrices, p = 0.0345 for WT/ MYBPC3−/− 
comparison on 10 µm matrices). Data b (n = 3): mean ± SD with all data. Data c (n = 4): box 
plot with minimum, maximum, median, 25% and 75%. Data e (n = 6): box plot with 
minimum, maximum, median, 25% and 75%.
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